Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
AMPE.US
id: 110
D. Colorado
Court
The company announced that an independent special committee of the Ampio Board of Directors, with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relates to, among other matters, Ampio's AP-013 clinical trial and other clinical trials.
On August 03, 2022, Company issued a letter to Shareholders covering the initial results of the investigation. Special Committee's primary findings include that certain former Ampio executive officers and senior staff were aware, at the time of the per-protocol interim analysis in March 2020, that the AP-013 trial did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function; and that these former Ampio executive officers and senior staff did not fully report the results of the AP-013 trial and the timing of unblinding of data from the AP-013 trial.

Case Status
Attorney Investigation
Alleged Offence
Misleading Statements
Fraud
Failure to Disclose
Malpractice
Negligence
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
16 May 2022
Collecting participants…

Ampio Pharm

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA...

    Ticker
    AMPE.US
    ISIN
    US03209T1097
    CIK
    1411906
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    9800 Mount Pyramid Court, Englewood, CO, United States, 80112